NorthRock Partners LLC Sells 1,533 Shares of Boston Scientific Corporation $BSX

NorthRock Partners LLC decreased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 9.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,947 shares of the medical equipment provider’s stock after selling 1,533 shares during the quarter. NorthRock Partners LLC’s holdings in Boston Scientific were worth $1,605,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of BSX. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific during the 1st quarter worth approximately $27,000. Sound Income Strategies LLC grew its position in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $37,000. Finally, Activest Wealth Management grew its position in shares of Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 373 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Wells Fargo & Company raised their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC reissued a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Wednesday, October 1st. UBS Group lifted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Finally, Robert W. Baird lifted their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $120.71.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $94.92 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock’s fifty day simple moving average is $101.75 and its two-hundred day simple moving average is $101.84. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The stock has a market cap of $140.64 billion, a PE ratio of 56.50, a price-to-earnings-growth ratio of 2.30 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the business earned $0.62 EPS. The business’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.